Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 7/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570922 | 1.00 | CFD (0.41) | CFDTSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3577280 | 0.88 | CFD (0.48) | CFDTSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3579963 | 0.83 | POLB (0.52) | TSHRALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL3579831 | 0.83 | CFD (0.42) | CFDTSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3575319 | 0.82 | POLB (0.49) | TSHRALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL3580290 | 0.81 | SMN1; SMN2 (0.42) | CFDTSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3579267 | 0.78 | CFD (0.41) | CFDTSHRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3574125 | 0.76 | POLB (0.47) | ALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL8096462 | 0.74 | CYP2C19 (0.52) | TSHRALDH1A1CYP2C9CYP2C19KMT2A | |
| SCHEMBL13119596 | 0.74 | CYP2C19 (0.52) | TSHRALDH1A1CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | CFD 335/4885TSHR 2691/4885ALDH1A1 4057/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | CFD 335/4885TSHR 2691/4885ALDH1A1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.